SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as discussions highlight its privacy features and potential scalability through Layer-2 solutions like Starknet, with some community members suggesting it could become the 'new Bitcoin'. The asset's recent price action and increasing volume are also fueling speculation about further gains, while its connection to Cypherpunk Technologies, backed by the Winklevoss twins, is attracting attention.

this coin is scarce

Traders are closely watching SCARCE CRYPTO, suggesting it may be primed for a significant move. The community highlights its potential for a breakout due to its low supply and consolidating price action, while some express skepticism regarding its true scarcity.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending amid discussions about its potential to scale Bitcoin and Ethereum using ZK-STARK technology, with some community members drawing comparisons to Zcash ($ZEC) due to its privacy features. The launch of BTCFi season with significant $STRK incentives has further fueled interest, alongside protocol upgrades and increased developer activity. Some users are also pointing out that the ticker is labeled as Strike Coin, while it is actually Starknet.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The crypto $SLAP is currently trending with community members expressing excitement and the phrase "WAGMI" (We Are All Going To Make It). The community is actively promoting the project, highlighting its team, staking rewards, partnerships with athletes, and real-world events. Some users are also questioning what $SLAP is all about.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market experiences volatility, leading to discussions about potential bottom levels and future growth. Community members are debating the impact of institutional investments, the upcoming Fusaka upgrade, and its decoupling from Bitcoin's price action. Some traders express concerns over market manipulation and potential bearish trends, while others remain optimistic about Ethereum's long-term utility and adoption.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the OG meme coin, emphasizing its legacy and the "OG MEME SZN." Discussions highlight the project's strong community, the return to meme culture, and the potential for significant growth. The focus remains on community belief and shared success.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

TWLO is trending amid discussions around potential breakouts and price targets, with analysts weighing in on its growth prospects and AI integration. Community members are actively debating entry points and whether the stock can sustain its recent gains. The stock's performance is also being compared to competitors in the CPaaS space, like BAND.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as traders discuss potential breakouts and a possible rotation into Chinese equities, highlighting the ETF's attractive valuations relative to the U.S. market. Recent discussions center on China's economic data, trade relations, and potential government actions impacting the sector. The community is closely watching technical patterns and awaiting catalysts that could drive KWEB higher.

Memecoin on Injective taken over by the community.

Nonja

Nonja is trending as the community rallies behind its potential as a leading meme coin on the Injective ($INJ) ecosystem, especially with the recent developments around Injective's EVM mainnet and potential ETF approvals. Community members emphasize the coin's strong community, high burned liquidity (reducing rug pull risk), and successful NFT collections. Discussions also highlight Nonja's historical performance and potential for significant gains if Injective gains further traction.

The Hartford Insurance Group, Inc. is an insurance and financial services company. It operates through the following segments: Commercial Lines, Personal Lines, Property & Casualty Other Operations, Group Benefits, Hartford Funds, and Corporate. The Commercial Lines segment provides workers' compensation, property, automobile, liability and umbrella coverage under several different products. The Personal Lines segment offers standard automobile, homeowners, and personal umbrella coverage to individuals. The Property & Casualty Other Operations segment includes certain property and casualty operations, managed by the company, that have discontinued writing new business and substantially all of the company's asbestos and environmental exposures. The Group Benefits segment provides group life, accident, and disability coverage, as well as group retiree health and voluntary benefits. The Hartford Funds segment offers investment products for retail and retirement accounts and provides investment management and administrative services. The Corporate segment includes corporate category discontinued operations, reserves for run-off structured settlement, and terminal funding agreement liabilities, restructuring costs, and capital raising activities. The company was founded by Terry Nathaniel on May 10, 1810, and is headquartered in Hartford, CT.

Hartford Insurance Group Inc.(The)

Hartford Financial Services Group Inc.

$HIG is trending due to a mix of technical signals and analyst ratings activity, with community members noting its potential as a stable investment. The stock's RSI indicates overbought conditions, sparking discussion around possible pullbacks and entry points for short positions. Several firms have updated their price targets and ratings, influencing investor sentiment and highlighting potential long-term value.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Pessimistic Estimate for CLDX Earnings

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at HC Wainwright reduced their FY2025 earnings per share estimates for Celldex Therapeutics in a report released on Tuesday, November...

FY2025 Earnings Estimate for CLDX Issued By Leerink Partnrs

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Celldex Therapeutics in a research note...

FY2025 Earnings Forecast for CLDX Issued By Lifesci Capital

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Analysts at Lifesci Capital dropped their FY2025 earnings estimates for Celldex Therapeutics in a report released on Monday, November 10th...

What is Lifesci Capital's Forecast for CLDX FY2025 Earnings?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Lifesci Capital reduced their FY2025 earnings estimates for Celldex Therapeutics in a research note issued to...

Celldex Therapeutics, Inc. $CLDX Shares Sold by Fox Run Management L.L.C.

Fox Run Management L.L.C. lowered its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 41.4% in the second quarter, according to the company in its most recent Form 13F...

Barclays Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price

Barclays reduced their price target on shares of Celldex Therapeutics from $25.00 to $21.00 and set an "underweight" rating on the stock in a research report on Tuesday...

Celldex Therapeutics (NASDAQ:CLDX) Announces Quarterly Earnings Results

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) released its earnings results on Monday. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing...

Are Medical Stocks Lagging  ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.00	--	--	N/A
Q3 '25	-$0.90	-$1.01	-12.25%	MISSED
Q2 '25	-$0.86	-$0.85	0.68%	BEAT
Q1 '25	-$0.75	-$0.81	-7.29%	MISSED
Q4 '24	-$0.74	-$0.71	3.71%	BEAT

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest CLDX News

CLDXCelldex Therapeutics Inc.